Showing 3631-3640 of 9151 results for "".
- NPF Welcomes Four New Board Membershttps://practicaldermatology.com/news/npf-welcomes-four-new-board-members/2461907/The National Psoriasis Foundation (NPF) is adding four new members to the NPF Board of Directors. Andrew Blauvelt, MD, MBA, Valerie Harrison, PhD, Brian Janssen, and Diana Sandler, MD. will serve two-year terms effective July 1, 2023. Dr. Blauvelt will also serve as the Chair
- RoC Skincare Expands The Look Forward Project to Instill Optimism Among the Next Generationhttps://practicaldermatology.com/news/roc-skincare-expands-the-look-forward-project-to-instill-optimism-among-the-next-generation/2461905/RoC Skincare is expanding The RoC Look Forward Project in partnership with Sarah Jessica Parker. The initiative was first launched in 2022 to celebrate the power of optimism and its positive impact on long-term health and wellbeing. Now, the Look Forward
- Practical Dermatology® Unveils New Cover Redesign for July 2023 Issuehttps://practicaldermatology.com/news/practical-dermatology-unveils-new-cover-redesign-for-july-2023-issue/2461895/Bryn Mawr Communications, publisher of Practical Dermatology®, has announced a captivating new cover redesign for the magazine, which will debut with their upcoming July issue. This visual update signals the first of many changes coming to the publication. "We are thrilled to unveil our s
- Taylor Harris Named New CEO at Cuterahttps://practicaldermatology.com/news/taylor-harris-named-new-ceo-at-cutera/2461892/Taylor Harris has been appointed Chief Executive Officer for Cutera, Inc., effective August 7, 2023. Mr. Harris will succeed Sheila Hopkins, who has been serving as Interim Chief Executive Officer since April 2023. Mr. Harris and Ms. Hopkins will both continue serving as memb
- Network Meta-analysis: Oral Isotretinoin Is the Most Effective Acne Treatmenthttps://practicaldermatology.com/news/network-meta-analysis-oral-isotretinoin-is-the-most-effective-acne-treatment/2461888/Oral isotretinoin, followed by topical antibiotic, benzoyl peroxide and retinoid, are most effective acne treatments, according to a network meta-analysis of 221 randomized controlled trials. For the study, researchers investigated the effectiveness of various pharmacological
- AAD, Janssen, and Kenvue Mentor Next Generation of Dermatologistshttps://practicaldermatology.com/news/aad-janssen-and-kenvue-mentor-next-generation-of-dermatologists/2461884/As part of
- Almirall on Track for Net-Zero GHG emissions by 2050https://practicaldermatology.com/news/almirall-on-track-for-net-zero-ghg-emissions-by-2050/2461877/The Science-Based Targets initiative (SBTi) has validated Almirall’s Environmental, Social and Governance (ESG) targets to achieve net zero greenhouse gas (GHG) emissions across the value chain by 2050, under the 'Net-Zero Standard'. The company has als
- Enspectra Health Awarded NIH Grant to Advance Predictive Algorithms for AKshttps://practicaldermatology.com/news/enspectra-health-awarded-nih-grant-to-advance-predictive-algorithms-for-aks/2461874/Enspectra Health scored $2M in grant funding from the National Cancer Institute (NCI) to support research for developing deep learning algorithms to predict which actinic keratosis (AK) lesions, are likely to progress to squamous cell carcinoma (SCC). Enspectra's technolog
- Venus Concept Announces Medical Advisory Board for AI.ME, Its Next Generation Robotic Platformhttps://practicaldermatology.com/news/venus-concept-announces-medical-advisory-board-for-aime-its-next-generation-robotic-platform/2461872/Meet Venus Concept Inc.’s medical advisory board for AI.ME, its next generation robotic platform. The primary mission of the medical advisory board will be to provide strategic input, guidance, and clinical recommendations regarding the Company's emerging robotic technolo
- FDA Clears Xstrahl’s Radiant Aura for NMSCshttps://practicaldermatology.com/news/fda-clears-radiant-aura-receives-us-food-and-drug-administration-fda-510k-clearance/2461871/The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Xstrahl’s Radiant Aura, an office-based radiation therapy for non-melanoma skin cancer (NMSC). “We developed Radiant Aura to deliver both electronic brachytherapy and superficial radiation therapy in